J. Ruelle

发表

Study of the HIV-2 Env Cytoplasmic Tail Variability and Its Impact on Tat, Rev and Nef

Nordine Bakouche, P. Goubau, A. Vandenbroucke, 2013, PloS one.

Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants

P. Lacor, C. Verhofstede, D. Van Beckhoven, 2015, BMC Infectious Diseases.

Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium

P. Lemey, R. Paredes, R. Kaiser, 2019, Front. Microbiol..

Phylogenetic analysis of the Belgian HIV-1 epidemic reveals that local transmission is almost exclusively driven by men having sex with men despite presence of large African migrant communities.

M. Van Ranst, K. Van Laethem, C. Verhofstede, 2018, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients

V. Haufroid, L. Elens, N. Gengler, 2018, Scientific Reports.

Immune reconstitution inflammatory syndrome due to Mycobacterium genavense in an HIV-infected patient: Impact of rapid species identification by rpoB sequencing on clinical management

E. André, L. Goeminne, A. Colmant, 2015 .

Effectiveness of the South African expanded program of immunization against hepatitis B in children infected with human immunodeficiency virus‐1 living in a resource‐limited setting of Kwazulu‐Natal

J. Beghin, P. Goubau, J. Ruelle, 2017, Journal of medical virology.

HIV-1 and HIV-2 differentially regulate NF-κB activity during the late stages of the replication cycle through BST-2/tetherin antagonism

M. Lucchetti, L. Tafforeau, M. Sanou, 2020, bioRxiv.

Modulation of the NF-κB signaling pathway by the HIV-2 envelope glycoprotein and its incomplete BST-2 antagonism.

M. Lucchetti, E. André, Anandi Martin, 2018, Virology.

HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability

A. D. De Bel, D. Piérard, P. Goubau, 2012, BMC Infectious Diseases.

Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.

F. Brun-Vézinet, A. Calmy, A. van Sighem, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

K. Van Laethem, C. Verhofstede, J. Schmit, 2008, BMC infectious diseases.

Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso.

M. Sanou, Hsin-Fu Liu, P. Goubau, 2007, AIDS research and human retroviruses.

Human immunodeficiency virus type 1 (HIV-1) proviral DNA load in purified CD4+ cells by LightCycler® Real-time PCR

P. Henrivaux, P. Goubau, J. Ruelle, 2005, BMC infectious diseases.

Comparison of Methods for In-House Screening of HLA-B*57:01 to Prevent Abacavir Hypersensitivity in HIV-1 Care

J. Philippé, P. Van Acker, L. Vandekerckhove, 2015, PloS one.

Quality Control Assessment of Human Immunodeficiency Virus Type 2 (HIV-2) Viral Load Quantification Assays: Results from an International Collaboration on HIV-2 Infection in 2006

F. Brun-Vézinet, B. Rodés, J. Albert, 2008, Journal of Clinical Microbiology.

HIV-2 Treatment in Mali and Drug Resistance Antiretroviral Profile

P. Tulkens, S. Dao, A. A. Oumar, 2019, International STD Research & Reviews.

HIV2EU: supporting standardized HIV‐2 drug resistance interpretation in Europe

C. Charpentier, R. Kaiser, F. Brun-Vézinet, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir

A. Ternes, J. Schmit, S. Dao, 2010, Retrovirology.

Quantitative real-time PCR on Lightcycler for the detection of human immunodeficiency virus type 2 (HIV-2).

M. Schutten, P. Goubau, J. Ruelle, 2004, Journal of virological methods.

Decision tree for accurate infection timing in individuals newly diagnosed with HIV-1 infection

K. Van Laethem, L. Hebberecht, C. Verhofstede, 2017, BMC Infectious Diseases.

A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium

P. Lemey, R. Paredes, R. Kaiser, 2017, Virus evolution.

Late presentation to HIV testing is overestimated when based on the consensus definition

M. Van Ranst, A. Pharris, M. Moutschen, 2015, HIV medicine.

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study

C. Morrison, F. Brun-Vézinet, F. Dabis, 2017, The Journal of antimicrobial chemotherapy.

Meticulous Plasma Isolation is Essential to Avoid False Low-Level Viraemia in Roche Cobas HIV-1 Viral Load Assays

C. Verhofstede, J. Ruelle, T. Van Maerken, 2018, Antiviral therapy.

Validation of an ultrasensitive digital droplet PCR assay for HIV-2 plasma RNA quantification

P. Goubau, Patrick Goubau, Jean Ruelle, 2014, Journal of the International AIDS Society.

Drug resistance in HIV-infected children living in rural South Africa: Implications of an antiretroviral therapy initiated during the first year of life.

J. Beghin, P. Goubau, J. Ruelle, 2020, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Moving forward with treatment options for HIV-infected children

J. Beghin, J. Yombi, J. Ruelle, 2018, Expert opinion on pharmacotherapy.

Near Full-Length Characterization and Population Dynamics of the Human Immunodeficiency Virus Type I Circulating Recombinant Form 42 (CRF42_BF) in Luxembourg.

D. Struck, J. Schmit, M. Nijhuis, 2015, AIDS research and human retroviruses.

HIV-2: A summary of present standard of care and treatment options for HIV-2 infected individuals living in Western Europe.

C. Charpentier, R. Kaiser, J. Rockstroh, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Human Immunodeficiency Virus–2 (HIV-2): A Summary of the Present Standard of Care and Treatment Options for Individuals Living with HIV-2 in Western Europe

C. Charpentier, R. Kaiser, J. Rockstroh, 2020, Clinical Infectious Diseases.

HIV-2EU-Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update.

C. Charpentier, R. Kaiser, F. Brun-Vézinet, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Role of Raltegravir in the Treatment of HIV-2 Infections: Evidence from a Case Series

M. Vekemans, R. Colebunders, F. Siegal, 2012, Antiviral therapy.

HIV-2: Testing Specificities

J. Ruelle, 2012 .

Reliability of species detection in 16S microbiome analysis: Comparison of five widely used pipelines and recommendations for a more standardized approach

A. Hiergeist, S. Emler, J. Ruelle, 2023, PloS one.

Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A.

M. Suchard, P. Lemey, N. Taveira, 2012, The Journal of general virology.

Virological and Immunological Long-Term Outcome of Human Immunodeficiency Virus-1 Infected Children Treated before One Year and after Two Years of Age in a Resource-Limited Setting of South Africa

D. Linden, J. Beghin, P. Goubau, 2017 .

An International Collaboration To Standardize HIV-2 Viral Load Assays: Results from the 2009 ACHIEV2E Quality Control Study

G. Gottlieb, M. Wainberg, F. Brun-Vézinet, 2011, Journal of Clinical Microbiology.